Cholinesterase inhibitors history

Pulmonary Prescribe cholinesterase inhibitors with care for patients with a history of asthma or obstructive pulmonary disease. 

These findings from the natural history of untreated Alzheimer s disease and how it is modified by cholinesterase inhibitors should help prescribers set realistic expectations for treatment with AChE inhibitors. The hope is that today s improvements from cholinesterase inhibition will be synergistic when combined with agents of differing pharmacologic mechanisms of action in the future and should be considered a very useful first step in treating this devastating illness. 

Basic and advanced life support measures should be utilized as necessary for atropine exposure. Gastric decontamination procedures should be employed based on the patient s history and current symptomatology. Activated charcoal can be given to adsorb atropine. The mainstay of treatment is supportive care. Physostigmine, a cholinesterase inhibitor, can be given to patients to reverse signs and symptoms of... 

In Section III, we review studies on persistent effects of exposure to cholinesterase inhibitors. The human epidemiological literature is examined for evidence that persistent behavioral effects of exposure can be measured in populations with histories of acute poisoning and/or chronic ongoing exposure. We then review behavioral data from animal models designed to characterize the behavioral changes caused by experimental treatments with cholinesterase-inhibiting pesticides and identify similarities with the literature on human.s exposed occupationally to these compounds. 

---